Although growth inhibition of HER2-overexpressing cancer cell lines by trastuzumab (1–100 μg ml−1) with maximally 50% of control was observed in vitro, it was less extensive than that by gefitinib (Figure 5AvsFigure 2A). The gene discussed is ERBB2; the disease is cancer.